
Baby born with rare life-threatening disorder makes medical history
The experimental therapy, crafted specifically for his condition, corrected a minute yet crucial error in his genetic code, offering hope for others with similarly rare diseases.
The infant, KJ Muldoon of Clifton Heights, Pennsylvania, was diagnosed shortly after birth with severe CPS1 deficiency.
This condition, estimated to affect roughly one in a million babies, prevents the body from effectively removing ammonia, leading to potentially toxic buildup in the bloodstream.
While liver transplants can be a solution for some, this innovative gene-editing treatment offers a new avenue of hope.
The study, published in the New England Journal of Medicine, details KJ's case and highlights the potential of this technology.
Dr. Kiran Musunuru, a University of Pennsylvania gene editing expert and study co-author, hailed the treatment as "the first step towards the use of gene editing therapies to treat a wide variety of rare genetic disorders for which there are currently no definitive medical treatments."
KJ's case represents a significant advancement in personalized medicine, demonstrating the potential to tailor treatments to individual genetic profiles.
While widespread availability of such personalized therapies remains on the horizon, this success story offers a beacon of hope for the millions affected by rare genetic conditions often overlooked by mainstream medical advancements.
KJ is among the first to benefit from this cutting-edge approach, paving the way for future applications of gene editing in treating a broader spectrum of rare diseases.
Knowing KJ's odds, parents Kyle and Nicole Muldoon, both 34, worried they could lose him.
'We were, like, you know, weighing all the options, asking all the questions for either the liver transplant, which is invasive, or something that's never been done before,' Nicole said.
'We prayed, we talked to people, we gathered information, and we eventually decided that this was the way we were going to go,' her husband added.
Within six months, the team at Children's Hospital of Philadelphia and Penn Medicine, along with their partners, created a therapy designed to correct KJ's faulty gene. They used CRISPR, the gene editing tool that won its inventors the Nobel Prize in 2020. Instead of cutting the DNA strand like the first CRISPR approaches, doctors employed a technique that flips the mutated DNA 'letter' — also known as a base — to the correct type. Known as 'base editing," it reduces the risk of unintended genetic changes.
It's 'very exciting' that the team created the therapy so quickly, said gene therapy researcher Senthil Bhoopalan at St. Jude Children's Research Hospital in Memphis, who wasn't involved in the study. 'This really sets the pace and the benchmark for such approaches.'
In February, KJ got his first IV infusion with the gene editing therapy, delivered through tiny fatty droplets called lipid nanoparticles that are taken up by liver cells.
While the room was abuzz with excitement that day, 'he slept through the entire thing,' recalled study author Dr. Rebecca Ahrens-Nicklas, a gene therapy expert at CHOP.
After follow-up doses in March and April, KJ has been able to eat more normally and has recovered well from illnesses like colds, which can strain the body and exacerbate symptoms of CPS1. The 9 ½-month old also takes less medication.
Considering his poor prognosis earlier, 'any time we see even the smallest milestone that he's meeting – like a little wave or rolling over – that's a big moment for us,' his mother said.
Still, researchers caution that it's only been a few months. They'll need to watch him for years.
'We're still very much in the early stages of understanding what this medication may have done for KJ,' Ahrens-Nicklas said. 'But every day, he's showing us signs that he's growing and thriving.'
Researchers hope what they learn from KJ will help other rare disease patients.
Gene therapies, which can be extremely expensive to develop, generally target more common disorders in part for simple financial reasons: more patients mean potentially more sales, which can help pay the development costs and generate more profit. The first CRISPR therapy approved by the U.S. Food and Drug Administration, for example, treats sickle cell disease, a painful blood disorder affecting millions worldwide.
Musunuru said his team's work — funded in part by the National Institutes of Health — showed that creating a custom treatment doesn't have to be prohibitively expensive. The cost was 'not far off' from the $800,000-plus for an average liver transplant and related care, he said.
'As we get better and better at making these therapies and shorten the time frame even more, economies of scale will kick in and I would expect the costs to come down,' Musunuru said.
Scientists also won't have to redo all the initial work every time they create a customized therapy, Bhoopalan said, so this research 'sets the stage' for treating other rare conditions.
Carlos Moraes, a neurology professor at the University of Miami who wasn't involved with the study, said research like this opens the door to more advances.
'Once someone comes with a breakthrough like this, it will take no time" for other teams to apply the lessons and move forward, he said. 'There are barriers, but I predict that they are going to be crossed in the next five to 10 years. Then the whole field will move as a block because we're pretty much ready.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
an hour ago
- Daily Mail
Gut got YOU down? The science-backed $2 a day probiotic giving shoppers the 'life-saving' relief they've been searching for
Daily Mail journalists select and curate the products that feature on our site. If you make a purchase via links on this page we will earn commission - learn more Shoppers are transforming their gut this summer with a one-of-a-kind daily pill that contains a 3-in-1 formula from popular wellness brand Ritual. Ritual has been creating buzz for some time now with their gender specific multivitamins, and now it is their Synbiotic+ gel capsules that are taking center stage. The tiny daily pills are helping both men and women everywhere take back their gut with science-backed formulas. The best part about the increasingly sought-after daily health resource is that it is shockingly affordable. For a one-month supply, it is only $60 — that breaks down to roughly $2 per dose (which, when we are talking about wellness, is low). So why Synbiotic+? Unlike other brands of gut health pills, Ritual uses a 3-in-1 approach. The daily capsules combine prebiotics, probiotics, and postbiotics into one pint-sized pill that goes down smooth and has a refreshing minty essence. By going beyond the typical probiotic blend, the unique formula can more effectively combat gut health. Each capsule contains 11 billion CFUs from live bacteria strains and 15mg of prebiotics, both of which help balance the gut by encouraging healthy bacteria growth. Users have seen a major difference in their bodies after using Synbiotic+, with one saying: ' Synbiotic+ saved my life! Not to be dramatic, but it's true. 'I dealt with horrible stomach issues for a year and a half... I've been on it for over a year, and it's been a total game changer.' The clinically tested and approved Synbiotic+ Gut Health capsules go through rigorous testing for quality control, including third-party testing. One human colon study done in Belgium with ProDigest revealed and confirmed that the majority of the Synbiotic+ components made it to the colon in a viable form! If you struggle with your gut, whether it be from certain foods you eat or when to travel, no matter the circumstance, Ritual's top-rated capsules will become your biggest game-changer. They are helping users all over restore their gut immunity one day at a time. One user even said: 'I have been dealing with severe bloating and stomach pain almost every day for the past few years. Despite trying to eat clean and changing my diet, I noticed how it has been affecting my daily life. Then, I decided to give Ritual a try. 'After using it for just 3 weeks, I have experienced so much relief and consistency!' Try out Ritual's Synbiotic+ Gut Health capsules for yourself ASAP to give your gut a new lease on life and if you want to get more bang for your buck, subscribe for 20 percent off!


Daily Mail
2 hours ago
- Daily Mail
BREAKING NEWS Horror as eight children from same choir suffer SEIZURES while performing at Massachusetts concert
Eight children from the same choir were raced to hospital mid-performance after suffering seizures in a church. The horror episode unfolded around 7pm Monday in Cambridge, Massachusetts, as the children all experienced seizures at the same time. Some of the children said that they started feeling unwell during their choir performance at St. Paul's Parish church due to an odor, reports WCVB. Witnesses also told first responders they smelled an odor, however crews reportedly said they did not detect any strange smells when they arrived. All of the children were aged between 11 and 13 and were originally from France. Cambridge Fire Chief Thomas Cahill said that the situation 'quickly escalated', and said the children were all transported to nearby hospitals. Their condition is unknown. 'This was somewhat unusual,' Cahill said. 'It was a routine medical call that quickly escalated into transporting eight children to the hospital. Not common.'


Reuters
2 hours ago
- Reuters
Boston Scientific lifts annual profit view on steady heart devices demand
July 23 (Reuters) - Boston Scientific (BSX.N), opens new tab raised its annual profit forecast on Wednesday, after strong demand for its heart devices helped the U.S. medical device maker beat second-quarter profit estimates. Shares of the Massachusetts-based company rose 2.3% in premarket trading following the results. A rise in surgical procedures has benefited medical device manufacturers such as Boston Scientific, as it boosted sales and helped offset broader concerns about healthcare spending pressures. Analysts said hospital utilization trends were robust during the second quarter, with hospital checks pointing to high single-digit volume growth - well above the historical average. Boston Scientific's main growth drivers, Farapulse and Watchman, which use short high-voltage pulses to treat certain abnormal heart rhythm conditions, saw strong demand during the quarter. Farapulse, approved in the U.S. to treat certain patients with intermittent atrial fibrillation, competes with Johnson & Johnson's (JNJ.N), opens new tab Varipulse and Medtronic's (MDT.N), opens new tab PulseSelect in the market for pulsed field ablation (PFA) systems. "Cardiovascular end-markets remain robust," Truist analyst Richard Newitter said ahead of the earnings, adding that Boston, followed by Medtronic, are in the best position at the moment to benefit from the growing and accelerating PFA market. Rival Johnson & Johnson last week posted strong medtech sales, aided by its heart devices, Varipulse and Trupulse. Boston Scientific expects 2025 adjusted profit of $2.95 to $2.99 per share, up from the prior view of $2.87 to $2.94 earlier. It posted adjusted profit of 75 cents per share for the second quarter, topping analysts' average estimate of 72 cents, according to data compiled by LSEG. The company's cardiovascular unit reported quarterly sales of $3.34 billion, surpassing estimates of $3.20 billion. Revenue came in at $5.06 billion for the quarter, topping estimates of $4.9 billion.